Using this model, we subsequently tested the in vivo efficacy of sirolimus (rapamycin), a current drug therapy, which we found reduces hamartoma size but also significantly disrupts the morphology of the peripheral retina, where Pten is uniformly deleted. This evidence concerns the gene PTEN and hamartoma.